Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Toshiaki Takahashi, MD, PhD"'
Autor:
Kosei Doshita, MD, Yuya Tabuchi, MD, Hirotsugu Kenmotsu, MD, PhD, Shota Omori, MD, Takanori Kawabata, MD, Hiroaki Kodama, MD, Naoya Nishioka, MD, PhD, Eriko Miyawaki, MD, PhD, Yuko Iida, MD, PhD, Nobuaki Mamesaya, MD, Haruki Kobayashi, MD, Ryo Ko, MD, PhD, Kazushige Wakuda, MD, Akira Ono, MD, PhD, Tateaki Naito, MD, PhD, Haruyasu Murakami, MD, PhD, Keita Mori, PhD, Hideyuki Harada, MD, PhD, Takeshi Kaneko, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
Advances in Radiation Oncology, Vol 8, Iss 2, Pp 101129- (2023)
Purpose: This study aimed to clarify the characteristics of and evaluate the risk factors for radiation pneumonitis (RP) induced by chemoradiation therapy (CRT) using accelerated hyperfractionated (AHF) radiation therapy (RT) in patients with limited
Externí odkaz:
https://doaj.org/article/ff29a9793bab47478d01d6840d0a25e3
Autor:
Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171- (2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic
Externí odkaz:
https://doaj.org/article/3e75f1f8e2034c7bb7923044f4c4d8a7
Autor:
Taichi Miyawaki, MD, Tateaki Naito, MD, PhD, Akihro Kodama, MD, Naoya Nishioka, MD, Eriko Miyawaki, MD, Nobuaki Mamesaya, MD, Takahisa Kawamura, MD, PhD, Haruki Kobayashi, MD, Shota Omori, MD, Kazushige Wakuda, MD, Akira Ono, MD, PhD, Hirotsugu Kenmotsu, MD, PhD, Haruyasu Murakami, MD, PhD, Akifumi Notsu, PhD, Keita Mori, PhD, Hideyuki Harada, MD, PhD, Masahiro Endo, MD, PhD, Kazuhisa Takahashi, MD, PhD, Toshiaki Takahashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 1, Iss 2, Pp 100020- (2020)
Introduction: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) i
Externí odkaz:
https://doaj.org/article/b4419d311f174e4794372d4d06ea913f